A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort
Blood · 28.11.2024 · 144 (22) · 2360-2363
DOI: 10.1182/blood.2024025834 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Blood, erschienen am 28.11.2024. Verfasst von Mendel Goldfinger und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Decitabine, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for patients with acute myeloid leukemia and a TP53-mutation was 16.1 and 11.3 months, respectively. This trial was registered at www.clinicaltrials.gov as #NCT05184842.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY.
- Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
- Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA.
- Sarah Cannon Research Institute, Research Medical Center, Kansas City, MO.
- Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
ORCID-Profile: Mendel Goldfinger, Yogen Saunthararajah, Kira Gritsman, Nishi Shah, Lauren C Shapiro, Brian A Jonas, Yang Shi, Marina Konopleva, Amit Verma
Förderung
- NCI NIH HHS
Zitieren
APA
Goldfinger, M., Mantzaris, I., Shastri, A., Saunthararajah, Y., Gritsman, K., Sica, R. A., Kornblum, N., Shah, N., Levitz, D., Rockwell, B., Shapiro, L. C., Gupta, R., Pradhan, K., Xue, X., Munoz, A., Dhawan, A., Fehn, K., Comas, M., Verceles, J. A., …, & Verma, A. (2024). A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood, 144(22), 2360-2363. https://doi.org/10.1182/blood.2024025834
Vancouver
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica RA, et al. A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood. 2024;144(22):2360-2363. doi:10.1182/blood.2024025834
BibTeX
@article{Goldfinger2024,
author = {Goldfinger, Mendel and Mantzaris, Ioannis and Shastri, Aditi and Saunthararajah, Yogen and Gritsman, Kira and Sica, R Alejandro and Kornblum, Noah and Shah, Nishi and Levitz, David and Rockwell, Bradley and Shapiro, Lauren C and Gupta, Ridhi and Pradhan, Kith and Xue, Xiaonan and Munoz, Anne and Dhawan, Aradhika and Fehn, Karen and Comas, Monica and Verceles, Jhannine Alyssa and Jonas, Brian A and Kambhampati, Suman and Shi, Yang and Braunschweig, Ira and Cooper, Dennis L and Konopleva, Marina and Feldman, Eric J and Verma, Amit},
title = {A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort},
journal = {Blood},
year = {2024},
volume = {144},
number = {22},
pages = {2360--2363},
doi = {10.1182/blood.2024025834}
}
EUVIMED